Unknown

Dataset Information

Preclinical evaluation and preliminary clinical study of <sup>68</sup>Ga-NODAGA-NM-01 for PET imaging of PD-L1 expression.


ABSTRACT:

Background

Programmed cell death 1/programmed death ligand-1 (PD-L1)-based immune checkpoint blockade is an effective treatment approach for non-small-cell lung cancer (NSCLC). However, immunohistochemistry does not accurately or dynamically reflect PD-L1 expression owing to its spatiotemporal heterogeneity. Herein, we assessed the feasibility of using a 68Ga-labeled anti-PD-L1 nanobody, 68Ga-NODAGA-NM-01, for PET imaging of PD-L1.

Methods

Micro-PET/CT and biodistribution studies were performed on PD-L1-positive and -negative tumor-bearing mice. Additionally, a preliminary clinical study was performed on two patients with NSCLC. NM-01 was radiolabeled with 68Ga without further purification under mild conditions.

Results

68Ga

SUBMITTER: Zhao L 

PROVIDER: S-EPMC11771120 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature